Our top pick for
Zosano Pharma Corporation is a biotechnology business based in the US. Zosano Pharma Corporation shares (ZSAN) are listed on the NASDAQ and all prices are listed in US Dollars. Zosano Pharma Corporation employs 45 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.33 - $1.96|
|50-day moving average||$1.18|
|200-day moving average||$0.90|
|Wall St. target price||$2.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.81|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-21,569,000|
|Return on assets TTM||-37.33%|
|Return on equity TTM||-117.28%|
|Market capitalisation||$99.2 million|
TTM: trailing 12 months
There are currently 7.9 million Zosano Pharma Corporation shares held short by investors – that's known as Zosano Pharma Corporation's "short interest". This figure is 4.5% down from 8.2 million last month.
There are a few different ways that this level of interest in shorting Zosano Pharma Corporation shares can be evaluated.
Zosano Pharma Corporation's "short interest ratio" (SIR) is the quantity of Zosano Pharma Corporation shares currently shorted divided by the average quantity of Zosano Pharma Corporation shares traded daily (recently around 4.1 million). Zosano Pharma Corporation's SIR currently stands at 1.9. In other words for every 100,000 Zosano Pharma Corporation shares traded daily on the market, roughly 1900 shares are currently held short.
However Zosano Pharma Corporation's short interest can also be evaluated against the total number of Zosano Pharma Corporation shares, or, against the total number of tradable Zosano Pharma Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zosano Pharma Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Zosano Pharma Corporation shares in existence, roughly 70 shares are currently held short) or 0.0759% of the tradable shares (for every 100,000 tradable Zosano Pharma Corporation shares, roughly 76 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zosano Pharma Corporation.
Find out more about how you can short Zosano Pharma Corporation stock.
We're not expecting Zosano Pharma Corporation to pay a dividend over the next 12 months.
Zosano Pharma Corporation's shares were split on a 1:20 basis on 25 January 2018. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zosano Pharma Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Zosano Pharma Corporation shares which in turn could have impacted Zosano Pharma Corporation's share price.
Over the last 12 months, Zosano Pharma Corporation's shares have ranged in value from as little as $0.3275 up to $1.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zosano Pharma Corporation's is 3.9355. This would suggest that Zosano Pharma Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.